This may be the first Mizuho Financial Group price target that I've seen in the biotech industry in my 20 years of trading - I'd take this price target with a grain of salt. Ziopharm has a drug in phase 2 trials which will report around the end of the year but they are a long way from commercializing anything (if ever) and already carry a heft $540 million+ market cap.
Ziopharm Climbs 12% After $11 Price Target From Mizuho Financial Group
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.